News | Published:

First-in-class biologic to enter rheumatoid arthritis fray

Nature Biotechnologyvolume 23pages13231324 (2005) | Download Citation

Subjects

A completely novel biologic for the treatment of rheumatoid arthritis is poised to enter the US market.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

  1. Ann Arbor, Michigan

    • Ken Garber

Authors

  1. Search for Ken Garber in:

Related links

Related links

Web links

Bristol-Myers Squibb

About this article

Publication history

Published

Issue Date

DOI

https://doi.org/10.1038/nbt1105-1323

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing